Top

Cancer Immunology, Immunotherapy

Published in:

01-06-2008 | Original Article

Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy

Authors: Alison Merrick, Rosa Maria Diaz, Dearbhaile O’Donnell, Peter Selby, Richard Vile, Alan Melcher

Published in: Cancer Immunology, Immunotherapy | Issue 6/2008

Abstract

Background

Dendritic cells (DC) pulsed with MHC class I-restricted tumour associated antigen (TAA) peptides have been widely tested in pre-clinical models and early clinical studies for their ability to prime cytotoxic T cell (CTL) responses. The effect of co-expression of allogeneic MHC antigens on DC immunogenicity has not been addressed, and has implications for the feasibility of clinical applications.

Objective

This study compared DC from autologous H-2^b or semi-allogeneic F1 H-2^bxk mice pulsed with the H-2^b-restricted model ovalbumin (OVA) peptide SIINFEKL, and compared in vitro and in vivo their ability to (i) activate specific OT1 cells, (ii) prime naïve CTL, and (iii) protect against B16.OVA challenge. Peptide-pulsed autologous and allogeneic DC were also tested in naïve human CTL priming assays.

Results

Semi-allogeneic DC expressed higher levels of co-stimulatory molecules. On pulsing with SIINFEKL they triggered greater proliferation of OT1 cells in vitro and in vivo, but were less effective at naïve CTL priming and tumour protection. Autologous human DC were similarly more potent at naïve CTL priming against the melanoma-associated TAA MART-1 in vitro.

Conclusion

The expression of allogeneic MHC antigens on peptide-pulsed DC impairs naïve CTL priming and anti-tumour effects, despite effective TAA presentation both in vitro and in vivo.

Banchereau J et al (2005) Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother 28(5):505–516PubMedCrossRef

Guermonprez P et al (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667PubMedCrossRef

Rescigno M et al (1997) Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol 61(4):415–421PubMed

Smits HH et al (2005) Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 26(3):123–129PubMedCrossRef

Ferlazzo G (2005) Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 101(1):12–17PubMedCrossRef

Melcher A et al (2002) Dendritic cells for the immunotherapy of cancer. Clin Oncol (R Coll Radiol) 14(3):185–192

Gong J et al (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3(5):558–561PubMedCrossRef

Phan V et al (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 9(9):1215–1219PubMedCrossRef

Plautz GE et al (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90(10):4645–4649PubMedCrossRef

10.

Errington F et al (2006) Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 12(4):1333–1341PubMedCrossRef

11.

Neves AR et al (2005) Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother 54(1):61–66PubMedCrossRef

12.

Hus I et al (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19(9):1621–1627PubMedCrossRef

13.

Holtl L et al (2005) Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54(7):663–670PubMedCrossRef

14.

Gong J et al (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165(3):1705–1711PubMed

15.

Tanaka Y et al (2001) Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101(2):192–200PubMedCrossRef

16.

Siders WM et al (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7(4):498–505PubMedCrossRef

17.

Suzuki T et al (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 11(1):58–66PubMed

18.

Wells JW et al (2007) Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity. Cancer Immunol Immunother 56(12):1861–1873PubMedCrossRef

19.

Tirapu I et al (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 110(1):51–60PubMedCrossRef

20.

Chakraborty NG et al (2004) Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65(8):794–802PubMedCrossRef

21.

Babatz J et al (2006) Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 55(3):268–276PubMedCrossRef

22.

Wierecky J et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66(11):5910–5918PubMedCrossRef

23.

Melcher A et al (1999) Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res 59(12):2802–2805PubMed

24.

Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5(11):1249–1255PubMedCrossRef

25.

Inaba K et al (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176(6):1693–1702PubMedCrossRef

26.

Petersen MS et al (2000) Strain-specific variations in the development of dendritic cells in murine bone-marrow cultures. Scand J Immunol 51(6):586–594PubMedCrossRef

27.

Gallucci S, Matzinger P (2001) Danger signals: SOS to the immune system. Curr Opin Immunol 13(1):114–119PubMedCrossRef

28.

Yasuda T et al (2007) Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56(7):1025–1036PubMedCrossRef

Title: Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy
Authors: Alison Merrick
Rosa Maria Diaz
Dearbhaile O’Donnell
Peter Selby
Richard Vile
Alan Melcher
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0426-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2008

Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors

Dendritic cell vaccination and other strategies to tip the balance of the immune system

Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update

Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity

CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells

Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer